Skip to content
Peptigraph home
Shop Peptides50% off*

Mazdutide for Weight Loss: What the Evidence Shows

What human and animal studies show about Mazdutide for weight loss, how strong that evidence is, and what is still unproven.

Medical review pendingGLP-1 / glucagon dual agonistUpdated
Strongest evidence
Human RCT
Human studies
8
with an outcome for weight loss, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for weight loss, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
9
with an outcome for weight loss

Evidence for weight loss

Each row is an outcome related to weight loss from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Mazdutide for weight loss: outcomes in published studies
OutcomeResultStudy typeSource
Body weight at week 60 (coprimary)Body weight changed by -16.65% with mazdutide versus -1.50% with placebo at week 60.Human RCTn = 461JAMA 2026, PMID 42251595
Body weight at week 32 (primary)At 32 weeks body weight changed by -18·1% with 16 mg, -15·6% with 10 mg and -7·3% with 3-6 mg versus -0·9% with placebo.Human RCTn = 179The lancet. Diabetes & endocrinology 2026, PMID 42628555
Body weight at week 24Body weight changed by -7.81% with 6 mg and -5.61% with 4 mg versus -1.26% with placebo.Human RCTn = 320Nature 2026, PMID 41407859
Body weight vs dulaglutideBody weight differed by -3.78% (4 mg) and -5.76% (6 mg) versus dulaglutide.Human RCTn = 731Nature 2026, PMID 41407860
Body weight at week 32 (primary)At week 32 body weight changed by -12.55% with 6 mg and -10.09% with 4 mg versus +0.45% with placebo.Human RCTn = 610The New England journal of medicine 2025, PMID 40421736
Body weight at week 48At week 48 body weight changed by -14.01% with 6 mg and -11.00% with 4 mg versus +0.30% with placebo.Human RCTn = 610The New England journal of medicine 2025, PMID 40421736
Body weight at week 20Body weight changed by up to -7.1% with mazdutide versus -2.7% with dulaglutide and -1.4% with placebo at week 20.Human RCTDiabetes care 2024, PMID 37943529
Body weight at week 24 (primary)Body weight changed by -11.3% with 6 mg, -10.4% with 4.5 mg and -6.7% with 3 mg versus +1.0% with placebo at week 24.Human RCTn = 248Nature communications 2023, PMID 38092790
Body weight at week 12At week 12 body weight changed by -4.81% (3.0 mg), -6.40% (4.5 mg) and -6.05% (6.0 mg) versus +0.60% with placebo.Human RCTEClinicalMedicine 2021, PMID 34430840
Weight lossMazdutide reduced body weight by a mean difference of -6.22% versus placebo.Meta-analysisn = 680Frontiers in endocrinology 2024, PMID 38440786

Mazdutide and weight loss are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4JAMA 2026, PMID 42251595

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

The goal in plain terms

MedlinePlus defines obesity as a disease that means having too much body fat.[10]

Body-weight results by trial

In the phase 2 trial, week-24 body weight changed -6.7% with 3 mg, -10.4% with 4.5 mg and -11.3% with 6 mg of mazdutide, against 1.0% with placebo.[7]

In the phase 3 GLORY-1 trial, week-48 body weight changed -11.00% at the lower dose and -14.01% at the higher dose against 0.30% with placebo.[5]

In the higher-dose phase 3 trial, 84.3% of participants on mazdutide lost 5% or more of body weight at week 60, against 33.1% on placebo.[1]

A phase 1b study reported week-12 weight changes of -4.81%, -6.40% and -6.05% in each of the cohorts against 0.60% with placebo.[8]

Registered weight measures

The registry record for the GLORY-1 trial lists percent change from baseline in body weight as a measure.[11]

The diabetes trial NCT05606913 registered a composite of HbA1c under 7.0% and weight loss of at least 5% from baseline.[12]

Other peptides people research for weight loss

SemaglutideTirzepatideRetatrutideOrforglipronSermorelinTesamorelinhCGMOTS-c
All peptides for weight loss, compared

Common questions

Does Mazdutide help with weight loss?

The strongest study we summarise for weight loss is human rct evidence, across 9 studies with an outcome for weight loss. A trial result is not an approval; see the legal status.

Is Mazdutide approved for weight loss?

No. Mazdutide is not FDA approved for any use, including weight loss.

What is the best peptide for weight loss?

There is no single answer. Our weight loss overview compares each candidate by evidence grade and legal status rather than by popularity.

How much weight can you lose on mazdutide?

The trials report group averages, which differ by dose and by trial; the higher-dose phase 3 trial averaged -16.65% at week 60.[1]

More on Mazdutide

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Legal statusFDA, compounding and WADA status with dates.How to injectSites, syringe types and hygiene, step by step.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.JAMA · 2026PMID 42251595Accessed 2 Oct 2026
  2. 2Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
  3. 3Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
  4. 4Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
  5. 5Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
  6. 6Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Diabetes care · 2024PMID 37943529Accessed 2 Oct 2026
  7. 7A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.Nature communications · 2023PMID 38092790Accessed 2 Oct 2026
  8. 8IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
  9. 9Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2024PMID 38440786Accessed 2 Oct 2026
  10. 10Official web pageOfficial web page · web page
  11. 11A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
  12. 12Efficacy and Safety of IBI362 Versus Dulaglutide as add-on to Metformin and/or SGLT2 Inhibitor or TZD in Subjects With Type 2 Diabetes (DREAMS-2)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.